Safety of using a combinatorial pharmacogenomic test for patients with major depressive disorder in the GUIDED trial

Authors

Sagar V Parikh, University of Michigan - Ann Arbor
Gabriela K Khazanov, University of Pennsylvania
Michael E Thase, University of Pennsylvania
Anthony J Rothschild, University of Massachusetts Medical School
Boadie W Dunlop, Emory University
Charles DeBattista, Stanford University
Charles R Conway, Washington University School of Medicine in St. Louis
Brent P Forester, McLean Hospital
Richard C Shelton, University of Alabama, Birmingham
Matthew Macaluso, University of Kansas
James Li, Myriad Neuroscience
Kunbo Yu, Myriad Neuroscience
Michael R Jablonski, Myriad Neuroscience
Stephanie Meek, Myriad Genetics
John F Greden, University of Michigan - Ann Arbor

Journal

CNS Spectrums

Publication Date

2021

Volume

26

Issue

2

First Page

169

Last Page

170

Document Type

Open Access Publication

DOI

10.1017/S1092852920002746

Rights and Permissions

Parikh SV, Khazanov GK, Thase ME, et al. Safety of Using a Combinatorial Pharmacogenomic Test for Patients with Major Depressive Disorder in the GUIDED trial. CNS Spectr. 2021;26(2):169-170. doi:10.1017/S1092852920002746. © The Author(s), 2021. Published by Cambridge University Press. https://www.cambridge.org/core

Recommended Citation

Parikh, Sagar V; Khazanov, Gabriela K; Thase, Michael E; Rothschild, Anthony J; Dunlop, Boadie W; DeBattista, Charles; Conway, Charles R; Forester, Brent P; Shelton, Richard C; Macaluso, Matthew; Li, James; Yu, Kunbo; Jablonski, Michael R; Meek, Stephanie; and Greden, John F, "Safety of using a combinatorial pharmacogenomic test for patients with major depressive disorder in the GUIDED trial." CNS Spectrums. 26, 2. 169 - 170. (2021).
https://digitalcommons.wustl.edu/open_access_pubs/10477